Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence. (3rd June 2021)

• Record Type: Journal Article
• Authors: Boltjes, Robin; Knippenberg, Stephanie; Gerlach, Oliver; Hupperts, Raymond; Damoiseaux, Jan
• Is Part Of: Expert review of neurotherapeutics. Volume 21:Number 6(2021)
• Page Start: 715
• Page End: 725
• Publication Date: 2021-06-03
• Subjects: Vitamin D -- Multiple Sclerosis -- 25-hydroxyvitamin D -- vitamin D supplementation; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2021.1935878
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction: Vitamin D has long been known for its immune-modulating effects, next to its function in calcium metabolism. As a consequence, poor vitamin D status has been associated with many diseases including multiple sclerosis (MS). Epidemiological studies suggest an association between a poor vitamin D status and development of MS and a poor vitamin D status is associated with more relapses and faster progression after patients are diagnosed with MS. Area's covered: The aim of the authors was to review the role of vitamin D supplementation in the treatment of MS. Pubmed was used to review literature with a focus of vitamin D supplementation trials and meta-analyses in MS. Expert opinion: There is no solid evidence to support the application of vitamin D therapy, based on current available supplementation trials, although there are some promising results in the clinically isolated syndrome (CIS) patients and young MS patients early after initial diagnosis. The authors recommend further larger clinical trials with selected patient groups, preferable CIS patients and young patients at the time of diagnosis, using vitamin D3 supplements to reach a 100 nmol/l level, to further investigate the effects of vitamin D supplementation in MS.